Pharmaceutical Import Taxes at Present

The global pharmaceutical industry, a complex network of nations and products, is bracing for potential changes following an investigation announced by the US administration in 2026. The focus of this investigation is the national security implications of pharmaceutical imports, separate from broader tariffs.

The United States produces 12 percent of total Active Pharmaceutical Ingredients (APIs) domestically, including High-Potency Small-Molecule APIs (HPAPIs) and biologic APIs. However, pharmaceutical products remain the 5 largest category of goods that the US imports, with most generic drugs, by volume, produced in India. The top producer of antibiotics is China, while Ireland exports the most synthetic hormones, and the US is the second largest exporter.

Switzerland, on the other hand, leads in API production by value, specializing in higher cost APIs for branded and specialty drugs. Branded APIs coming from Europe represent 43 percent of all branded APIs.

The outcome of the 232 investigation has been indicated by President Trump to call for a gradual ramping up of tariffs over several years, potentially reaching 250 percent. However, for countries that are parties to a 1994 WTO agreement to eliminate tariffs on pharmaceuticals, the final tariff rate is likely to be the same for all of them, with the highest potential tariff for pharmaceuticals seeming to be 15 percent, as per the EU agreement.

If the Section 232 investigation sets tariff levels for pharmaceuticals higher than the current favored 10-15 percent tariff cap, the countries most affected would primarily be the European Union countries and China. This is due to the fact that imports of pharmaceuticals, semiconductors, and wood from the EU are subject to Section 232 tariffs capped at 15 percent, though a higher rate could apply if raised by the investigation. China could be significantly affected due to ongoing U.S. tariffs linked to trade disputes under Section 232.

Countries that didn't sign the WTO agreement will face tariff rates determined by the Section 232 investigation, which may be uniform, country-specific, or determined by individual trade deals.

In an effort to control drug prices in the US, President Trump has also been pursuing the Most Favored Nation policy, compelling drug companies to sell drugs in the US at prices no greater than they sell them for in other developed countries.

This investigation and the potential tariffs it may bring will have complex effects on the pharmaceutical supply chain, given its intricate nature. The outcome remains to be seen, but it is clear that the global pharmaceutical industry is on the brink of significant change.

Source: https://pangea-network.com/top-10-largest-us-imports-2024/